Literature DB >> 50402

Cross-resistant relationships among the aminoglucoside antibiotics in Mycobacterium tuberculosis.

M Tsukamura, S Mizuno.   

Abstract

Phenotypes of isolates of Mycobacterium tuberculosis H37RV showing resistance to the aminoglucoside antibiotics streptomycin, viomycin, kanamycin, capreomycin, tuberactinomycin N, lividomycin and paromomycin could be grouped into the following types: (I) resistant only to different levels of streptomycins; (2) resistant only to a low level of kanamycin; (3) triply resistant, to low levels of viomycin, tuberactinomycin N and capreomycin; (4) triply resistant, to a low level of kanamycin and high levels of lividomycin and paromomycin; (5) quadruply resistant, to a low level of capreomycin and high levels of kanamycin, lividomycin and paromomycin; (6) hextuply resistant, to high levels of viomycin, tuberactinomycin N, capreomycin, kanamycin, lividomycin, and paromomycin. Three modificatied types of the latter were also observed. Appearance rates of the six types were estimated as 10(-6) to 10(-9), 10(-6), 10(-6) to 10(-7), 10(-8), 10(-8), and 10(-8) to 10(-9), respectively, in a total viable population of the parent strain. Mutations to all phenotypes were considered to be produced by single mutations. According to cross-resistance relationships, aminoglucoside antibiotics were classified into three groups: (I) streptomycin; (II) viomycin, tuberactinomycin N and capreomycin; (III) kanamycin, lividomycin and paromomycin. No cross-resistance relationship between streptomycin and other antibiotics was observed. Resistances to viomycin, tuberactinomycin N and capreomycin occurred by single mutation to type 3. Resistances to kanamycin, lividomycin and paromomycin occurred by single mutations to types 4 and 5. Low resistance to capreomycin was produced by mutation to type 5. Therefore capreomycin was considered to be an intermediate between the second and third groups. These two groups had a close relationship, as resistance to all six agents in these groups could be produced by a single mutation to type 6 (and its modified types).

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 50402     DOI: 10.1099/00221287-88-2-269

Source DB:  PubMed          Journal:  J Gen Microbiol        ISSN: 0022-1287


  9 in total

1.  Mutation detection and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India.

Authors:  Kanchan Ajbani; Camilla Rodrigues; Shubhada Shenai; Ajita Mehta
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

2.  Drug-resistant tuberculosis: what are the treatment options?

Authors:  Amr S Albanna; Dick Menzies
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

3.  Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis.

Authors:  G J Alangaden; B N Kreiswirth; A Aouad; M Khetarpal; F R Igno; S L Moghazeh; E K Manavathu; S A Lerner
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.

Authors:  Courtney E Maus; Bonnie B Plikaytis; Thomas M Shinnick
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis.

Authors:  Melisa Willby; R David Sikes; Seidu Malik; Beverly Metchock; James E Posey
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

6.  Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China.

Authors:  Z Zhang; M Liu; Y Wang; Y Pang; K M Kam; Y Zhao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-07       Impact factor: 3.267

7.  Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis.

Authors:  Courtney E Maus; Bonnie B Plikaytis; Thomas M Shinnick
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

8.  Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis.

Authors:  Annika Krüüner; Pontus Jureen; Klavdia Levina; Solomon Ghebremichael; Sven Hoffner
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

9.  Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery.

Authors:  Shelley E Haydel
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.